G
Giovanni Barosi
Researcher at Foundation Center
Publications - 61
Citations - 1781
Giovanni Barosi is an academic researcher from Foundation Center. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 19, co-authored 61 publications receiving 1561 citations. Previous affiliations of Giovanni Barosi include University of Illinois at Chicago & University of Verona.
Papers
More filters
Journal ArticleDOI
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Giovanni Barosi,Ruben A. Mesa,Juergen Thiele,Francisco Cervantes,Peter J. Campbell,Srdan Verstovsek,Brigitte Dupriez,Ross L. Levine,Francesco Passamonti,Jason Gotlib,John T. Reilly,Alessandro M. Vannucchi,C A Hanson,Lawrence A. Solberg,Attilio Orazi,Ayalew Tefferi +15 more
TL;DR: Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myel ofibrosis research and treatment.
Journal ArticleDOI
A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes
Pierluigi Rossi Ferrini,Alberto Grossi,Alessandro M. Vannucchi,Giovanni Barosi,Roberta Guarnone,Piva N,Pellegrino Musto,Enrico Balleari +7 more
TL;DR: To evaluate the effect of recombinant human erythropoietin (rHuEpo) on the haemoglobin level and transfusion requirement in low‐risk myelodysplastic syndromes (MDS), 87 patients were enrolled in a randomized double‐blind placebo‐controlled study.
Journal ArticleDOI
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Damiano Rondelli,Damiano Rondelli,Judith D. Goldberg,Judith D. Goldberg,Luis Isola,Luis Isola,Leah Price,Leah Price,Tsiporah B. Shore,Tsiporah B. Shore,Michael Boyer,Andrea Bacigalupo,Alessandro Rambaldi,Marco Scarano,Rebecca B. Klisovic,Rebecca B. Klisovic,Vikas Gupta,Bjorn Andreasson,John Mascarenhas,John Mascarenhas,Meir Wetzler,Meir Wetzler,Alessandro M. Vannucchi,Alessandro M. Vannucchi,Josef T. Prchal,Josef T. Prchal,Vesna Najfeld,Vesna Najfeld,Attilio Orazi,Attilio Orazi,Rona Singer Weinberg,Rona Singer Weinberg,Crystal Miller,Crystal Miller,Giovanni Barosi,Lewis R. Silverman,Lewis R. Silverman,Giuseppe Prosperini,Roberto Marchioli,Ronald Hoffman,Ronald Hoffman +40 more
TL;DR: In patients with MF with sibling donors, A HSCT is an effective therapy, whereas AHSCT from unrelated donors with FluMel/ATG conditioning led to a high rate of graft failure and limited survival, correlated with type of donor, but not with the degree of histocompatibility match.
Journal ArticleDOI
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli,Annalisa Pacilli,Giada Rotunno,Elisa Rumi,Vittorio Rosti,Federica Delaini,Margherita Maffioli,Tiziana Fanelli,Tiziana Fanelli,Alessandro Pancrazzi,Daniela Pietra,Silvia Salmoiraghi,Carmela Mannarelli,Annalisa Franci,Chiara Paoli,Alessandro Rambaldi,Francesco Passamonti,Giovanni Barosi,Tiziano Barbui,Mario Cazzola,Alessandro M. Vannucchi +20 more
TL;DR: Overt PMF was enriched in patients with anemia, thrombocytopenia, leukopenia, higher blast count, symptoms, large splenomegaly, and unfavorable karyotype, suggesting greater propensity to disease progression compared with pre-PMF.
Journal ArticleDOI
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
Valeria Santini,Paolo Emilio Alessandrino,Emanuele Angelucci,Giovanni Barosi,Atto Billio,M. Di Maio,Carlo Finelli,Francesco Locatelli,Monia Marchetti,Enrica Morra,Pellegrino Musto,Giuseppe Visani,Sante Tura +12 more
TL;DR: Since 2002, date of publication of the previous Italian Society of Haematology practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update.